FibroGen Looks to Regroup After Rocky Q2 Results, Ongoing Challenges

FibroGen endured clinical setbacks and a leadership shake-up in recent months, but the California biotech remains optimistic about its path forward, the company said Monday during its second-quarter 2023 earnings report.